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Histone deacetylase inhibitors induce cell cycle 
arrest and apoptosis in tumor cells and are 
therefore promising anti-cancer drugs. The 
CDK inhibitor p21 is activated in HDAC 
inhibitor treated tumor cells and its growth-
inhibitory function contributes to the anti-
tumorigenic effect of HDAC inhibitors. We 
show here that induction of p21 by trichostatin 
A involves MAP kinase signaling. Activation of 
the MAP kinase signaling pathway by growth 
factors or stress signals results in histone H3 
serine 10 phosphorylation at the p21 promoter 
and is crucial for acetylation of the 
neighboring lysine 14 and recruitment of 
activated RNA polymerase II in response to 
trichostatin A treatment. In non-induced cells, 
the protein phosphatase PP2A is associated 
with the p21 gene and counteracts its 
activation. Induction of p21 is linked to 
simultaneous acetylation and phosphorylation 
of histone H3. The dual modification mark 
H3S10phK14ac at the activated p21 promoter 
is recognized by the phospho-binding protein 
14-3-3 zeta, which protects the 
phosphoacetylation mark from being 
processed by PP2A. Taken together we have 
revealed a crosstalk of reversible 
phosphorylation and acetylation signals that 
controls the activation of p21 by HDAC 
inhibitors and identify the phosphatase PP2A 
as chromatin-associated transcriptional 
repressor in mammalian cells. 
  
Post-translational modifications (PTMs) of 
histones, such as acetylation, methylation, 
phosphorylation and sumoylation play important 
roles in the regulation of chromatin accessibility 
and gene expression. The transformation of a 
differentiated resting cell into a highly 
proliferative tumor cell is accompanied by a 
severe change of the gene expression profile, 
which in turn is the direct consequence of 
acquired/accumulated tumor suppressor- and 
oncogene mutations. In addition to these genetic 
alterations, epigenetic alterations are also 
involved in the development of cancer. These 
include covalent PTMs of histones and changes in 
the methylation status of cytosines within CpG 
islands (1,2). Therefore, compounds that target 
these epigenetic changes are of potential interest 
for anti-tumor therapies. Indeed, histone 
deacetylase (HDAC) inhibitors have been shown 
to induce cell cycle arrest, differentiation or 
apoptosis in tumor cells and are therefore 
promising anti-tumor drugs (3-5).  
One of the genes that is activated by different 
HDAC inhibitors encodes the cyclin-dependent 
kinase (CDK) inhibitor p21cip1/waf1 (referred to as 
p21 thereafter) (3,4). The p21 protein is a member 
of the CIP/KIP family of cyclin dependent kinase 
inhibitors consisting of p21, p27, and p57. The 
different members of the CIP/KIP family share a 
conserved region at the NH2-terminus that is 
required and sufficient for the inhibition of 
cyclin/Cdk complexes (6,7). The p21 protein 
preferentially inactivates Cyclin E/Cdk2 
complexes, thereby blocking the inactivating 
phosphorylation of pRb, which represses genes 
important for S phase entry. In addition, p21 can 
bind to proliferating cell nuclear antigen (PCNA) 
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thus blocking DNA synthesis (8,9). Paradoxically, 
p21 also promotes in a concentration dependent 
manner the formation of active complexes by 
stabilizing the interaction between Cdk4/Cdk6 
and D-cyclins (10). In agreement with this finding 
expression of the p21 gene is activated by growth 
factors (11). Interestingly, p21 can also directly 
affect transcription by association with specific 
promoter regions or by binding to specific 
transcription factors or co-activators (12-15).  
The p21 gene is a transcriptional target of p53 and 
plays a crucial role in mediating growth arrest 
when cells are exposed to DNA-damaging agents 
such as doxorubicin and γ-irradiation (16,17). In 
addition to its role in DNA damage response, p21 
is also implicated in terminal differentiation, 
replicative senescence, and protection from p53-
dependent and independent apoptosis (18,19). 
The p21 gene is regulated by a plethora of 
transcription factors and transcriptional regulators 
and its activation is accompanied by histone 
hyperacetylation suggesting a negative regulatory 
role for HDACs (20-22). Indeed, several members 
of the HDAC family have been shown to repress 
p21 expression (3,23,24). Importantly, HDAC 
inhibitors can activate p21 transcription in the 
absence of p53 allowing for p21 induction in 
tumor cells lacking functional p53 (25,26).  
The activity of p21 contributes to the growth-
inhibitory effect of HDAC inhibitors but it is 
evident that also other factors are involved in this 
process (27-29). For instance, several other cell 
cycle regulators including gelsolin, p16, p27, and 
different cyclins are deregulated upon HDAC 
inhibition (5). In addition, p21, which is usually 
considered to act as a tumor suppressor, might 
also act as an oncogene (30). Along this line, a 
tumor promoting activity of p21 was recently 
shown in different mouse tumor models (31,32). 
Given the opposite functions of p21 in growth 
control and tumorigenesis it is crucial to 
understand the mechanism underlying the 
activation of the p21 gene by HDAC inhibitors. 
In this study we analyze in detail the mechanisms 
regulating p21 expression in response to HDAC 
inhibition. We show that histone H3 
phosphorylation at the p21 promoter is 
indispensable for the activation of the p21 gene 
by HDAC inhibitors. The activation of stress or 
mitogen activated signaling cascades in concert 
with HDAC inhibition leads to simultaneous S10 
phosphorylation and K14 acetylation 
(phosphoacetylation) of histone H3 at the p21 
promoter. We identify mitogen- and stress-
activated kinase 1 (MSK1) to be one of the 
kinases responsible for histone H3 
phosphorylation and demonstrate its importance 
for p21 gene activation. Further, we show for the 
first time that chromatin-associated protein 
phosphatase PP2A can act as transcriptional 
repressor in mammalian cells. Finally, we 
demonstrate that recognition of the 
phosphoacetylation mark by the adaptor protein 
14-3-3 ζ is important for p21 activation and this 
might be in part due to protection of the mark 
from dephosphorylation by PP2A.   
 
Experimental Procedures 
Cell Culture and drug treatment. Swiss 3T3 
mouse fibroblasts were grown in DMEM medium 
supplemented with 10% (v/v) FCS and 
antibiotics. For cell cycle arrest in G0 cells were 
serum-deprived for 72 hours using DMEM 
medium containing 0,2% (v/v) FCS.  Re-entry 
into the cell cycle was induced with 20% (v/v) 
FCS. The human glioblastoma cell line T98G was 
cultured in DMEM containing 10% (v/v) FCS and 
was arrested in G0 by reducing FCS to 0.2% (v/v) 
for 48 hours.   
Proliferating and resting cells were treated with 
trichostatin A (TSA, 165.5nM, Wako Pure 
Chemical Industries), subinhibitory concentration 
of anisomycin (188.5nM, Sigma) as previously 
described (33), okadaic acid (OA, 50nM, Sigma), 
H89 (10µM, Alexis Biochemicals) for different 
periods of time.  
RNA Extraction and RT-Real Time PCR. Total 
RNA was prepared from Swiss 3T3, and T98G 
cells using the TRIZOL Reagent (Invitrogen) 
according to the manufacture’s protocol. For RT-
Real Time PCR 1µg total RNA was reverse 
transcribed in cDNA using the iScriptTMcDNA 
synthesis kit (Bio-Rad). 5µl of a 1:10 dilution of 
cDNA was analyzed by SYBER green Real Time 
PCR using the Bio-Rad iCycler iQ system. 
Expression of p21 was normalized to the house-
keeping genes mouse hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) or human 
Glycerinaldehyd-3-phosphat-Dehydrogenase 
(GAPDH), whose expression is not affected by 
the nucleosomal response. Primer sequences are 
available on request.  
Histone Extraction, Dot Blot and Western blot 
analysis. Histone preparation and Western blot 
analysis were performed as previously described 
(Hauser et al., 2002). The following antibodies 
were used in this study: modification-specific 
antibodies against acetylated histone H3 (06-599) 
and H4 (06-866), H3K14ac (07-353) from 
Millipore Upstate Biotechnology; H3S10ph 
(Santa Cruz 8656-R); H3S10phK14ac (Seiser lab, 
(34)) C-terminal histone H3 antibody (Abcam 
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1791); phospho-MSK1 (Thr581) (Cell Signalling 
#959); 14-3-3 ζ (Santa Cruz Biotechnology); S5-
phosphorylated RNA Polymerase II (Bethyl Lab 
A300-655A), PP2A catalytic subunit (E. Ogris 
lab); beta-tubulin (Sigma T4026). 
Chromatin Immunoprecipitation Assays. ChIP 
assays were performed as described previously 
(35). Antibodies used in this study are listed 
above. Quantification of precipitated material was 
performed via quantitative Real-Time PCR using 
an iCycler iQ system from Bio-Rad and KAPA 
SYBR FAST qPCR MasterMix (Peqlab). Primer 
sequences are available on request. 
RNA Interference Experiments. T98G cells were 
transfected with siRNAs at a final concentration 
of 24nM using Lipofectamin 2000 (Invitrogen). 
Next day, cells were either serum-deprived (0,2% 
(v/v) FCS) for 48 hours or kept in proliferation 
medium containing 10% (v/v) FCS. The 
following siRNA oligonucleotides were used in 
this study: hMSK1 (Santa Cruz, sc-35977); h14-
3-3 ζ (Santa Cruz, sc-29583); hPP2A-Cα 
(Dharmacon, L-003598-00); hPP2A-Cβ 
(Dharmacon, L-003599-00); unspecific hRNA-A 
(Santa Cruz, sc-37007). 
In Vitro Phosphatase Assay and Protection Assay. 
Histones were isolated from resting 3T3 
fibroblasts, which were treated with anisomycin 
(180nM) for 1 h by acid extraction as described 
(35). Extracted histones were diluted to 1µM in 
phosphatase assay buffer (50mM Tris-HCl pH7.5, 
75mM NaCl, 0.1% β-mercaptoethanol, 0.1mM 
EDTA) and either pre-incubated with equimolar, 
two times or four times molar excess of 
recombinant 14-3-3ζ-GST for 2h at 4°C. In 
addition control samples without 14-3-3 ζwere 
performed. Phosphatase reactions were carried 
out by adding 0.5U PP2A A/C dimer (Millipore 
Upstate Biotechnology) for 2h at 30°C. Reactions 
were lyophilized resuspended in SDS-sample 
buffer and analyzed by immunoblotting.  
Statistical analysis. P values were calculated 




Activation of p21 expression by HDAC inhibition 
requires a second signal. In this study we 
intended to analyze the molecular mechanisms 
regulating the activation of the p21 gene in 
response to HDAC inhibitor treatment. Induced 
p21 transcription in response to HDAC inhibitor 
treatment of human tumor cells was previously 
shown to be accompanied by increased histone 
acetylation at the proximal p21 promoter region 
but not at the 3’ end of the gene (36) (Figure 1A). 
Similar results were also obtained with HDAC 
inhibitor treatment of Swiss 3T3 cells (data not 
shown). The proximal promoter region contains 
multiple binding sites for the transcription factors 
Sp1, Sp3 and AP2. Sp1/Sp3 was shown to be 
involved in the recruitment of HDACs and 
histone acetyltransferases (HATs) and to mediate 
the effect of the phosphatase inhibitor okadaic 
acid (20,23). In agreement with previous reports 
(23,37), HDAC inhibition by trichostatin A (TSA) 
led to strong induction of p21 expression in 
proliferating untransformed Swiss 3T3 mouse 
fibroblasts and transformed fibroblast lines COP8 
and Tau2 (Figure 1B, and data not shown). To 
test whether TSA mediated activation of p21 in 
untransformed fibroblasts is also linked to 
hyperacetylation of core histones we performed 
chromatin immunoprecipitation (ChIP) assays. As 
shown in Figure 1C, ChIP experiments with 
antibodies specific for either acetylated histone 
H3 or H4 demonstrated that TSA treatment of 
proliferating fibroblasts results in increased H3 
and H4 acetylation at the p21 promoter region. In 
agreement with previously published results (36), 
histone acetylation the 3’ end of the p21 gene was 
not affected by TSA treatment.  
The majority of cells in an adult mammalian 
organism is in the G0/G1 phase of the cell cycle. 
Therefore, we asked next whether the p21 gene is 
also activated by TSA in non-proliferating cells. 
To this end we analyzed p21 mRNA levels in 
serum-deprived resting Swiss 3T3 fibroblasts. In 
comparison to proliferating Swiss 3T3 cells 
expression of p21 was about 8-fold lower in 
resting fibroblasts. Interestingly, in the absence of 
growth factors the HDAC inhibitor TSA failed to 
activate p21 transcription (Figure 1D). Even 
longer periods of TSA treatment up to 9 hours did 
not induce p21 mRNA expression (data not 
shown). Strikingly, ChIP assays with acetyl H3 
and acetyl H4 antibodies revealed a strong TSA-
mediated increase in H3 and H4 acetylation at the 
p21 promoter in resting cells (Figure 1E). 
However, despite the observed histone 
hyperacetylation p21 transcription was not 
activated in resting cells suggesting the 
requirement for an additional signal. 
Expression of p21 is activated by inducers of the 
MAP kinase pathway and correlates with H3 
phosphoacetylation. An obvious difference 
between proliferating and resting cells is the 
activation status of mitogen-activated protein 
(MAP) kinase cascades. Serum-deprived cells 
lack stimulation of growth factors activated signal 
transduction pathways and thus arrest in the 
G0/G1 phase. In addition to growth factors, 
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cellular stress also activates MAP kinase cascades 
in resting fibroblasts, whereas without inducing 
cell cycle entry. We therefore asked, whether 
activation of the p38 MAP kinase pathway would 
affect p21 expression in TSA treated cells.  
The stress inducer anisomycin activates the p38 
MAP kinase pathway at low concentrations that 
have no effect on protein synthesis (38). To test 
the effect of stress and growth factor signals on 
p21 expression, serum-deprived mouse fibroblasts 
were stimulated for 1 hour with subinhibitory 
concentrations of anisomycin (188.5nM) or with 
20% fetal calf serum (FCS), alone or in 
combination with TSA. Analysis of p21 mRNA 
expression by Real Time PCR revealed a two-fold 
increase by both serum stimulation and 
anisomycin treatment, whereas TSA had hardly 
an effect on p21 levels (Figure 2A). Importantly, 
when TSA was used together with either of the 
MAPK activators anisomycin or FCS we 
observed an enhanced transcriptional activation, 
resulting in a 3.5-fold and a 3-fold induction of 
p21 expression, respectively. 
Activation of mitogen and stress activated kinase 
cascades leads not only to the activation of a 
variety of transcription factors but also to 
phosphorylation of HMG-14 (HMGN-1) and 
histone H3 known as the nucleosomal response 
(39). Phosphorylation of histone H3 at serine 10 
was previously shown to be associated with 
transcriptional activation of a variety of 
mammalian genes (40-45). Phosphorylation is 
targeted to a minute fraction of histone H3, which 
is also especially susceptible to hyperacetylation, 
resulting in simultaneous phosphorylation and 
acetylation of histone H3 referred to as 
phosphoacetylation (46). It is important to note 
that in proliferating cells a considerable part of 
the S10-phosphorylated histone H3 (H3S10ph) 
and phosphoacetylated histone H3 
(H3S10phK14ac) stems from the mitotic fraction. 
Indeed, compared to resting cells the abundance 
of histone isoforms H3S10ph and H3S10phK14ac 
but also H3K14ac was enhanced in proliferating 
Swiss 3I3 cells and anisomycin/TSA treated 
resting cells (Supplementary Figure 1A). To 
monitor local changes in histone H3 
phosphorylation we performed quantitative ChIP 
assays with an H3S10ph specific antibody. As 
shown in Figure 2B, local H3 phosphorylation at 
the p21 promoter increased in response to 
activation of MAP kinase cascades in resting cells 
by anisomycin or FCS. Simultaneous TSA 
treatment led to reduction in the H3S10ph signal. 
However, it is known that acetylation of 
neighboring lysine residues can negatively affect 
the recognition of the H3S10ph mark by this 
antibody due to epitope occlusion (Supplementary 
Figure 1B and references (35,46)). Therefore, we 
performed ChIP assays with an antibody 
specifically recognizing dually modified 
S10phK14ac histone H3 ((35), Supplementary 
Figure 1B). Using the H3S10phK14ac antibody, 
we detected H3 phosphoacetylation in response to 
anisomycin or FCS in resting fibroblasts (Figure 
2B). In both cases the phosphoacetylation signal 
was increased upon additional HDAC inhibition 
by TSA. Thus, the histone H3 phosphoacetylation 
patterns at the proximal p21 promoter closely 
parallel the transcriptional activation the p21 
gene. In contrast, histone H3 phosphorylation and 
phosphoacetylation were not induced at the 3’end 
of the p21 gene (Figure 2B, lower panel). Taken 
together active MAP kinase cascades are 
important for the induction of the p21 gene by 
TSA. 
Histone phosphorylation by MSK1 kinase is 
crucial for full p21 activation. Studies with 
MSK1 and MSK2 single and double knockout 
cells identified MSK1 and MSK2 as the major 
histone H3 serine 10 effector kinases downstream 
of the ERK- and p38-pathways (47). As a first 
step to analyze the contribution of histone 
phosphorylation to the activation of the p21 gene 
by HDAC inhibition, we used the protein kinase 
inhibitor H89. This compound was shown to 
inhibit rather specifically MSK1/MSK2 and the 
“nucleosomal response” without affecting 
phosphorylation of relevant transcription factors 
(48). As shown in Figure 2C, pre-treatment of 
resting mouse fibroblasts with H89 efficiently 
blocked the induction of p21 expression by 
combinatorial treatment with TSA and 
anisomycin. Similarly, H89 treatment 
significantly reduced the activation of the p21 
gene by anisomycin, TSA and anisomycin/TSA in 
proliferating Swiss 3T3 cells (Supplementary 
Figure 2). Thus, the nucleosomal response is 
important for activation of the p21 gene by these 
drugs. Accordingly, ChIP analysis revealed that 
H89 pre-treatment of anisomycin/TSA treated 
resting cells completely inhibited H3 
phosphoacetylation at the p21 promoter (Figure 
2D).  
Previously, a possible interrelationship between 
H3S10 phosphorylation and the acetylation of 
neighboring lysine residues was discussed 
(49,50). Therefore, we examined next whether 
H3S10 phosphorylation at the p21 promoter had 
an impact on acetylation of H3K14 in response to 
TSA/anisomycin treatment. ChIP assays using the 
H3K14ac antibody revealed that acetylation of 
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histone H3 at K14 was induced combinatorial 
treatment with TSA and anisomycin (Figure 2D). 
Blocking of the nucleosomal response by H89 
significantly reduced H3K14 acetylation at the 
p21 promoter in anisomycin/TSA treated cells 
suggesting a link between MAP kinase signaling 
and recruitment or activity of a H3K14 HAT.  
Next, we analyzed the effect of the nucleosomal 
response on transcriptional initiation of the p21 
gene. To this end we monitored by qRT-ChIP the 
recruitment of initiation-competent RNA 
polymerase II (RNAPII S5ph) (51) to the p21 
promoter. As shown in Figure 2D, RNAPII S5ph 
was recruited to the p21 promoter in response to 
combinatorial treatment with TSA and 
anisomycin and this recruitment was sensitive to 
the inhibitor of the nucleosomal response H89. 
Taken together, these data strongly suggest that 
H3 phosphorylation via the nucleosomal response 
is required for local H3K14 acetylation, 
recruitment of activated RNA polymerase II and 
induction of the p21 gene in response to 
anisomycin/TSA.  
However, it is important to note that H89 not only 
affects the enzymatic activity of MSK1 and 
MSK2 but can also inhibit other protein kinases 
including PKA, S6K1 and ROCK-II (52).  
Therefore we performed siRNA knockdown 
experiments in order to ask whether MSK1 is 
important for p21 gene activation. To this end, we 
abolished MSK1 expression in T98G human 
glioblastoma cells. Pilot experiments indicated 
significantly higher knockdown efficiencies in 
this cell line compared to mouse fibroblasts. 
T98G cells have a fibroblast like morphology and, 
similar to mouse fibroblasts, can be arrested in G0 
by serum deprivation (53). This is of advantage to 
study interphase phosphorylation of histone H3, 
as cells can be synchronized in G0 to exclude 
interference with mitotic phosphorylation. T98G 
cells were transfected with MSK1 siRNA or 
control siRNA, arrested for 48 hours and either 
left untreated or stimulated with anisomycin and 
TSA for 3 hours. Both mRNA and protein levels 
of MSK1 were significantly reduced in siRNA 
treated cells as shown by Real Time PCR and 
Western blot analysis (Figure 3A and 
Supplementary Figure 3A). Resting T98G 
glioblastoma cells showed an 8-fold increase in 
p21 expression upon combinatorial anisomycin 
and TSA treatment (Figure 3B). Importantly, p21 
activation by anisomycin alone or 
anisomycin/TSA was reduced in MSK1 depleted 
cells compared to resting control cells (Figure 3B 
and Supplementary Figure 3B). Activation of the 
p21 gene in resting T98G cells was accompanied 
by enhanced recruitment of MSK1 and induced 
histone H3 phosphoacetylation at the proximal 
p21 promoter (Figure 3C). Importantly, presence 
of the H3S10phK14ac mark at the p21 promoter 
was significantly reduced upon loss of MSK1 
suggesting that this enzyme is one of the crucial 
mediators of the nucleosomal response in T98G 
cells (Figure 3C). These data demonstrate an 
important role of MSK1 in p21 expression in 
response to stress signaling. 
The phosphatase inhibitor okadaic acid induces 
p21 expression and histone H3 phospho-
acetylation in proliferating cells. As histone H3 
phosphorylation is a reversible mark, specific 
phosphatases counteract kinase-mediated 
phosphorylation and its biological read-out. At 
the end of mitosis, the phosphatase PP1 removes 
H3S10ph marks that are placed at the G2/M 
transition by Aurora B (54,55). However, little is 
known about the phosphatases regulating S10 
dephosphorylation during interphase. Genetic 
studies in Drosophila suggest a role for PP2A in 
the regulation of heat shock regulated genes, 
which is linked to histone H3 phosphorylation 
(56,57). We therefore asked whether PP2A would 
play a role in the control of dynamic histone H3 
phosphorylation and p21 gene expression in 
mammalian cells. 
Fibroblasts were treated with the phosphatase 
inhibitor okadaic acid, which at low 
concentrations (50nM) specifically inhibits PP2A 
(and PP2A-related enzymes) without affecting 
PP1 activity (58,59). Okadaic acid treatment has 
been previously shown to activate p21 expression 
in human cancer cells (60). In resting mouse 
fibroblasts, okadaic acid treatment in the absence 
of MAP kinase signaling had no major impact on 
global phosphoacetylation levels and on p21 
expression (Figure 4A and data not shown). Only 
in combination with the MAP kinase inducer 
anisomycin p21 expression was elevated by 
okadaic acid to levels comparable with 
anisomycin/TSA treated cells. Therefore, we 
analyzed a putative effect of okadaic acid on 
phosphoacetylation and p21 expression in 
proliferating Swiss 3T3 fibroblasts. Cells were 
stimulated for five hours either with okadaic acid, 
or TSA alone or in combination. Treatment with 
TSA or okadaic acid alone induced 
phosphoacetylation of bulk histones and 
combination of okadaic acid with TSA gave even 
higher H3S10phK14ac signals (data not shown). 
Treatments with TSA or okadaic acid led to 17- 
or 4-fold increase respectively in p21 expression 
levels (Figure 4B). Combinations of okadaic acid 
with anisomycin or TSA had a synergistic effect 
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on the activation of the p21 promoter in 
proliferating fibroblasts. In accordance with 
higher p21 expression in proliferating cells 
(Figure 1) ChIP assays with the H3S10phK14ac 
antibody showed higher levels of H3 
phosphoacetylation at the p21 promoter in 
untreated proliferating cells compared to resting 
cells (compare Figure 4C with Figure 2D). This is 
in part due to the presence of mitotic cells with 
high H3S10 phosphorylation levels. Combined 
treatment with TSA and okadaic acid further 
enhanced H3 phosphoacetylation at the p21 
promoter (Figure 4C). These findings suggest that 
in the presence of growth factors (i.e. in 
proliferating cells) HDAC inhibitors and 
phosphatase inhibitors cooperate in the induction 
of phosphoacetylation and p21 expression, as the 
turnover of phosphate and acetyl moieties is 
blocked. These data also suggest PP2A (or a 
PP2A like phosphatase) to be involved in the 
regulation of p21 transcription.  
Chromatin-associated PP2A is a negative 
regulator of p21 expression. Next, we examined 
whether PP2A is directly associated with the p21 
promoter. We performed ChIP assays with resting 
3T3 cells after short-term treatment with 
anisomycin and TSA using the phosphoacetyl-H3 
antibody and an antibody specific for catalytic C-
subunit of PP2A. To assess a potential kinase 
recruitment, short-term kinetics of MSK1 
association and phosphoacetylation turnover were 
determined by ChIP assays. Resting fibroblasts, 
stimulated with anisomycin and TSA for 15, 30, 
60 and 180 minutes were subjected to ChIP 
analysis using antibodies specific for 
phosphoacetylated histone H3 (H3S10phK14ac), 
the catalytic subunit of PP2A and MSK1 (Figure 
4D). Signaling to the p21 gene was fast and 
coincided with a rapid recruitment of MSK1 to 
the p21 promoter only after 15 minutes of 
induction followed by increasing 
phosphoacetylation of p21-associated chromatin. 
MSK1 recruitment seemed to be a dynamic and 
transient event, which was reduced after 30 
minutes of stimulation. PP2A was present at the 
p21 promoter in resting, non-stimulated cells but 
was gradually reduced upon treatment with TSA 
and anisomycin, while local H3 
phosphoacetylation increased at the same time 
(Figure 4D). In agreement with the 
H3S10phK14ac ChIP data shown in Figure 2D; 
both MSK1 and PP2A were absent at the 3’end of 
the p21 gene (data not shown). 
To test whether PP2A is indeed a transcriptional 
repressor of the p21 gene, we ablated the 
expression of the catalytic C-subunit of PP2A in 
T98G cells. As mentioned above, the phosphatase 
inhibitor okadaic acid induced p21 expression 
only in proliferating cells. Therefore we depleted 
proliferating T98G cells simultaneously of both 
C-subunit isoforms (α and β) by siRNA-mediated 
knockdown. PP2A C-subunit mRNA and protein 
levels were efficiently reduced in knockdown 
cells (Figure 4E and Supplementary Figure 3C). 
Notably, loss of PP2A resulted in a more than 2-
fold increase in p21 expression in untreated 
proliferating T98G cells (Figure 4F). The levels 
of p21 mRNA was also induced upon loss of 
PP2A in anisomycin/TSA treated cells suggesting 
a modulating function of the phosphatase in MAP 
kinase stimulated cells. In summary, these data 
indicate a novel role of PP2A as negative 
regulator of p21 expression. 
The H3S10ph binding module 14-3-3 is required 
for p21 activation by the nucleosomal response. 
14-3-3 proteins are well-established phospho-
serine binding proteins and recently members of 
the 14-3-3 family were shown to bind histone H3 
phosphorylated serine 10 (61). Importantly, the 
binding affinities of 14-3-3 to phosphorylated 
histone H3 are increased by acetylation of 
neighboring lysine residues, especially lysine 14 
(62,63). Moreover, 14-3-3 epsilon and, in 
particular, 14-3-3 zeta (ζ) are required for 
transcriptional activation of the HDAC1 gene by 
anisomycin and TSA (64).   
We therefore investigated whether 14-3-3 ζ is 
required for p21 gene activation. To this end 
proliferating T98G cells were transfected with 
either 14-3-3 ζ specific siRNA or control siRNA 
resulting in efficient reduction of both mRNA and 
protein expression (Figure 5A and Supplementary 
Figure 3D). Expression of p21 in untreated and 
anisomycin/TSA stimulated 14-3-3 knockdown 
and control cells was monitored by Realtime PCR 
analysis. In resting T98G control cells, p21 
mRNA levels were 3.5-fold increased by 
combined anisomycin and TSA treatment (Figure 
5B). In 14-3-3 ζ knockdown cells, activation by 
anisomycin and TSA was significantly reduced, 
indicating a crucial role of 14-3-3 ζ for p21 
expression. Of note, in the absence of 
TSA/anisomycin treatment 14-3-3 ζ deficient 
proliferating T98G cells show a 50% reduction of 
p21 expression. In ChIP assays with a 14-3-3 ζ 
antibody we observed efficient recruitment of 14-
3-3 ζ to the proximal p21 promoter (Figure 5C). 
In a similar manner, 14-3-3 ζ was detected at the 
p21 promoter in anisomycin/TSA treated resting 
Swiss 3T3 fibroblasts (data not shown). MSK1 
knockdown experiments revealed that 14-3-3 ζ 
recruitment to the p21 promoter was reduced in 
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the absence of MSK1 (Supplementary Figure 4). 
To test whether loss of 14-3-3 ζ has effects on H3 
acetylation and phosphoacetylation at the p21 
gene, we performed ChIP assays with H3K14ac 
and H3S10phK14ac antibody in control and 14-3-
3 ζ knockdown cells. As shown in Figure 5C 
depletion of 14-3-3 ζ in resting T98G cells 
interfered with the TSA/anisomycin mediated 
increase in H3K14 acetylation and H3 
phosphoacetylation at the p21 promoter. 
Interestingly, dissociation of PP2A from the p21 
promoter in response to anisomycin/TSA is 
abolished in the absence of 14-3-3 ζ (Figure 5C). 
Similarly, H89 pretreatment blocked the 
dissociation of PP2A in anisomycin/TSA treated 
resting Swiss 3T3 fibroblasts and the presence of 
PP2A at the p21 promoter was enhanced upon 
loss of MSK1 (data not shown). These data 
support the idea that the recruitment of 14-3-3 in 
response to MAP kinase signaling has a positive 
impact on histone H3 phosphoacetylation at the 
p21 promoter.  
It was previously shown that 14-3-3 proteins are 
able to protect phosphorylated substrates against 
dephosphorylation by PP2A (65). To test for a 
potential protective role of 14-3-3 in the context 
of histone H3 phosphorylation, we performed in 
vitro H3 dephosphorylation assays with 
recombinant PP2A and 14-3-3 ζ. 
Phosphoacetylated histone H3 was isolated from 
serum-starved fibroblasts stimulated with 
anisomycin and TSA and used as a substrate for 
dephosphorylation by PP2A in the presence and 
absence of 14-3-3 ζ. Recombinant PP2A 
dephosphorylated serine10 of histone H3 in vitro. 
Strikingly, addition of increasing amounts of 
recombinant 14-3-3 ζ prevented H3S10 
dephosphorylation by PP2A (Figure 5D). In 
conclusion, our data suggest that one important 
function of 14-3-3 proteins in the context of p21 
gene regulation might be to protect the of 
phosphoacetylation mark at histone H3 from 
being processed by PP2A. 
 
Discussion 
MAP kinase activation sensitizes resting cells to 
HDAC inhibitor treatment. In this report we 
analyzed in details the mechanisms responsible 
for the activation of the CDK inhibitor gene p21 
by HDAC inhibitor treatment. Activation of p21 
by HDAC inhibitors can occur in the absence of 
functional p53 (25,26) and is therefore of 
particular interest for cancer treatment as 
mutations of the tumor suppressor p53 are often 
contributing to tumor development. Here we 
report that MAP kinase activation by growth 
factors or stress has an important role in the 
transcriptional regulation of the p21 gene by 
HDAC inhibitors. In transformed cells and 
proliferating fibroblasts the HDAC inhibitor TSA 
induces histone hyperacetylation at the p21 
regulatory region and p21 expression. In contrast, 
TSA-induced histone hyperacetylation is not 
sufficient to activate p21 expression in resting 
cells i.e. in the absence of growth factors. The 
inability of HDAC inhibitors to activate the p21 
gene in resting cells is not limited to TSA but was 
also observed with other HDAC inhibitors such as 
valproic acid and MS-275 (unpublished data). 
Our data suggest that stimulation of the MAP 
kinase pathway with growth factors or stress 
inducers is required to sensitize resting fibroblasts 
to HDAC inhibitor treatment. 
Regulation of p21 by the nucleosomal response. 
MAP kinase signaling to the nucleosome, the so-
called nucleosomal response, is involved in the 
regulation of several important biological 
processes such as stress response, cancerogenesis, 
control of circadian rhythms and neuronal 
signaling circuits (66-68).  We show here that the 
nucleosomal response is required for activation of 
the p21 gene by HDAC inhibitor treatment. 
Blocking kinase signaling to the nucleosome with 
the inhibitor H89 prevents H3 phosphoacetylation 
at the p21 promoter, recruitment of activated 
RNA Pol II and expression of p21. Simultaneous 
treatment with the stress inducer anisomycin and 
TSA had a synergistic effect on p21 expression 
and H3 phosphoacetylation levels. Similarly, we 
observed induced H3 phosphoacetylation at the 
p21 promoter along with increased expression 
upon TSA treatment of cells with activated MAP 
kinase pathways such as proliferating fibroblasts 
and transformed cells (data unpublished). These 
data suggest that in both resting and proliferating 
cells the active p21 gene is marked by 
H3S10phK14ac. 
A variety of genes has been shown to be induced 
by mitogen or stress dependent signaling to the 
nucleosome (40). However, the detailed 
mechanism regulating the appearance of 
acetylation and phosphorylation marks is different 
for individual target genes. For instance similar to 
p21, c-fos and c-jun promoter-associated 
chromatin becomes hyperacetylated in response 
to HDAC inhibitor treatment without concomitant 
induced gene expression (33). However, p21 
induction by anisomycin is enhanced by 
simultaneous TSA treatment, whereas 
transcriptional activation of c-jun in response to 
stress signaling was shown to be abolished by 
HDAC inhibitors (69). In contrast to p21, c-fos 
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and c-jun, the HDAC1 gene can be activated in 
resting fibroblasts by TSA alone (35). It is 
conceivable that parameters such as promoter 
architecture, presence of individual transcription 
factor binding sites and additional epigenetic 
marks affect the recruitment of histone kinases 
and HATs in response to MAP kinase signaling.  
Phosphorylated histone H3 is highly susceptible 
to HDAC inhibitor induced hyperacetylation of 
neighboring lysine residues resulting in 
phosphoacetylated histone H3 (46).  Therefore, a 
direct link between histone acetylation and H3S10 
phosphorylation was previously discussed. For 
instance, in vitro assays showed that S10 
phosphorylation increased the affinity of the 
H3K14 acetylating HAT Gcn5 for histone H3 
suggesting a direct link between H3S10 
phosphorylation and K14 acetylation (50,70). On 
the other hand, blocking the nucleosomal 
response by kinase inhibitors did not diminish 
histone H3 acetylation at the c-jun promoter in 
response to anisomycin (33). We show here that 
the nucleosomal response is not only required for 
RNA Pol II recruitment to the p21 promoter but 
also important for efficient local H3K14 
acetylation. Recruitment or activation of the 
H3K14 specific HAT activity seems to be largely 
dependent on H3S10 phosphorylation, while 
inhibitors of the nucleosomal response did not 
affect the association of the H3K9-specific 
activity.   
MSK1 and PP2A as antagonistic regulators of 
p21 expression. MSK1 and MSK2 have been 
shown to be the major histone H3 kinases 
mediating the nucleosomal response (47). In 
agreement with this report we find a prominent 
role of MSK1 in p21 activation. The presence of 
the kinase at the p21 promoter was rapidly 
enhanced upon anisomycin/TSA stimulation, 
leading to local histone H3 phosphorylation. As 
antagonist of MSK1, protein phosphatase PP2A is 
associated with chromatin at the silent p21 
promoter in resting cells. A first link between 
PP2A activity and transcriptional regulation came 
from genetic studies in Drosophila. In response to 
heat shock transcriptionally active heat shock loci 
show a dramatic accumulation of H3S10ph marks 
while global histone H3 phosphorylation 
decreases (71). Interestingly, Drosophila PP2A 
mutants display reduced H3 dephosphorylation at 
non-heat-shock genes during heat shock (56). 
In our study, treatment of proliferating cells with 
concentrations of okadaic acid known to 
specifically inhibit PP2A resulted in enhanced 
histone phosphoacetylation and significant 
increase in p21 expression, indicating that 
phosphatase activity is involved in p21 gene 
repression. Interestingly, the highest p21 
expression was observed upon simultaneous 
treatment with okadaic acid and TSA, suggesting 
that presence and stability of the phosphoacetyl 
H3 mark is crucial for transcriptional induction of 
p21.  
Remarkably, reduced presence of PP2A at the p21 
gene upon MAP kinase activation coincided with 
the onset of histone H3 phosphorylation 
suggesting a direct link between the PP2A 
activity and dephosphorylation of histone H3. The 
potential of PP2A to dephosphorylate histone H3 
was also shown in in vitro experiments ((56) and 
this study). Direct evidence that PP2A acts as a 
transcriptional repressor of the p21 gene was 
finally demonstrated by specifically depleting the 
catalytic subunit of PP2A. PP2A is a multi-
subunit holoenzyme that achieves substrate 
specificity via interaction with regulatory 
subunits. At the moment it is unclear, which of 
the known regulatory subunits mediate the 
specificity for phosphorylated histone H3. In 
summary our study reveals a novel function of 
PP2A as chromatin-modifier and transcriptional 
repressor in mammalian cells. 
14-3-3 ζ is important for p21 Gene Activation by 
the Nucleosomal Response. We and others have 
previously shown that 14-3-3 proteins recognize 
and bind phospho-acetylated histone H3 (61-63). 
In the present study, we demonstrate that 14-3-3 ζ 
plays an important role in the activation of the 
p21 gene by the nucleosomal response. The 
recruitment of 14-3-3 ζ to the p21 promoter 
strongly correlates with the presence of the 
H3S10phK14ac mark and activation of p21 
expression. Depletion of 14-3-3 ζ results in 
significant reduction of p21 expression. Recently, 
14-3-3 has been shown to act as scaffold protein 
for the recruitment of chromatin remodeling 
complexes to target genes of the nucleosomal 
response (72). In addition, 14-3-3 has been 
implicated in the regulation of transcriptional 
elongation upon kinase signaling. In mammalian 
cells, 14-3-3 was shown to recruit the H4K16 
acetyltransferase MOF resulting in acetylation 
dependent recruitment of the elongation factor P-
TEFb via the bromodomain protein BRD4 (73). 
In Drosophila, 14-3-3 recruits the 
acetyltransferase Elongator protein 3, which 
acetylates histone H3 at K9 (74).   
Our experiments establish a crucial role for 14-3-
3 proteins in the regulation of p21 promoter 
activity and suggest a potential novel role of 14-3-
3 in the context of chromatin modifications. The 
data presented in this study are compatible with 
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the idea that 14-3-3 ζ stabilizes the 
phosphoacetylation mark at the p21 promoter by 
protecting against PP2A activity. According to 
our model shown in Figure 6, triggering the 
nucleosomal response by anisomycin alone 
results in transient H3 phosphoacetylation and 
p21 induction. Combined treatment with TSA 
leads to enhanced phosphoacetylation at the p21 
promoter and thereby promotes stable recruitment 
of 14-3-3 ζ. Indeed, additional acetylation of 
neighboring lysine residues was shown to 
stabilize the interaction between 14-3-3 and the 
phosphorylated histone H3 tail (62,63).  Stable 
binding of 14-3-3 ζ to phosphoacetylated histone 
H3 prevents the dual mark from being processed 
by PP2A and might thereby stabilize the 
H3S10phK14ac mark at the p21 promoter 
resulting in prolonged p21 expression in response 
to combinatorial TSA/anisomycin treatment. This 
study adds an additional dimension to the concept 
of gene regulation by the nucleosomal response 
by introducing PP2A as chromatin-associated 
dephosphorylating enzyme and 14-3-3 as 
potential protector of the H3S10 mark.  
Based on our findings that histone acetylation and 
phosphorylation act in concert in the regulation of 
the cell cycle regulator p21 (and maybe other 
proliferation regulators) it is tempting to speculate 
that treatment of tumor cells with combinations of 
HDAC inhibitors and drugs with impact on H3 
phosphorylation might be more effective and/or 
specific as anti-proliferative agents. Experiments 
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Figure 1. Proliferating and resting mouse fibroblasts respond differently to the HDAC inhibitor 
TSA.  (A) Schematic view of the murine p21 gene. The three exons are depicted as black boxes and the 
regions analyzed by quantitative Real Time (qRT)-ChIP are indicated. (B) Proliferating Swiss 3T3 
mouse fibroblasts were kept either untreated or were treated with 165.5 nM TSA for 3 hours. Total 
RNA was extracted and reverse transcribed cDNA was used to quantify p21 mRNA levels by 
quantitative Real Time qRT PCR using HPRT as a housekeeping gene for normalization. (C) 
Formaldehyde cross-linked chromatin was prepared from proliferating cells treated with 165.5nM TSA 
for 3 hours. ChIP experiments were performed with an unspecific mouse IgG antibody as control, two 
antibodies specific for acetylated histones H3 (acH3) and H4 (acH4) and an antibody recognizing the 
C-terminus of histone H3 to correct for potential changes in nucleosomal density. DNA from the 
antibody-bound fraction and a 1/40 dilution of total input DNA (Input) isolated from the respective 
chromatin sample was analyzed by qRT-PCR, using primers specific for the p21 promoter (p21 prom) 
and the 3’ end of the p21 gene (p21 3’end) as control. ChIP results are shown as percentage of input 
corrected for changes in nucleosomal density. (D) Swiss 3T3 cells were arrested by serum deprivation 
for 72 hours and treated with 165.5nM TSA for 3 hours and analyzed by qRT PCR for p21 expression. 
(E) qRT-ChIP with unspecific antibody (IgG) and two antibodies specific for acetylated histones H3 
(acH3) and H4 (acH4) was performed as described in panel (C). 
 
Figure 2. Activated MAP kinase cascades are required for p21 expression. (A) Resting Swiss 3T3 
mouse fibroblasts were left untreated (-) or were treated with 165.5nM TSA alone (T), 188.5nM 
anisomycin alone (A), both drugs simultaneously (A/T) or were stimulated with 20% serum (F) either 
alone or in combination with 165.5nM TSA (F/T) for 1 hour. Total RNA was extracted and reverse 
transcribed cDNA was used to quantify p21 mRNA levels by qRT PCR using HPRT as a housekeeping 
gene for normalization. The difference in p21 expression between untreated resting cells and TSA 
treated cells is not significant (p-value > 0.05), whereas all other treatments resulted in significant 
changes in p21 expression. (B) Chromatin was prepared from cells treated as described in panel A and 
precipitated using an unspecific antibody (IgG), an histone H3S10ph antibody and an antibody 
specifically recognizing histone H3 phosphoacetylated on serine 10 and lysine 14 (H3S10phK14ac). 
Precipitated DNA was analyzed by qRT PCR using primers specific for the promoter (upper panel) and 
the 3’end (lower panel) of the p21 gene. Panels C and D: Resting Swiss 3T3 mouse fibroblasts were 
treated for 3 hours with 188.5nM anisomycin and 165.5nM TSA with (H89 + A/T) or without (A/T) 
pre-treatment for 15 minutes with 10µM H89. (C) Total RNA was extracted from stimulated cells and 
reverse transcribed cDNA was used for p21 expression analysis by qRT PCR. (D) ChIP assays of 
resting and anisomycin/TSA stimulated 3T3 cells in the presence and absence of H89. Chromatin was 
precipitated with an unspecific control antibody (IgG) or antibodies specific for H3S10phK14ac, 
H3K14ac, H3 C-terminus and initiation-competent RNA polymerase II (RNAP II phS5) and qRT PCR 
was performed with primers for the p21 promoter (p21 prom) and the 3’end of the p21 gene (p21 
3’end) as control. ChIP results are shown as percentage of input; for histone modifications the values 
were corrected for changes in nucleosomal density. 
 
Figure 3. The effector kinase MSK1 is important for p21 gene induction by TSA/anisomycin. 
Proliferating T98G cells were transfected with control siRNA oligonucleotides and siRNA 
oligonucleotides specifically targeting MSK1 mRNA for 5 hours. Next day transfected T98G cells 
were arrested by serum deprivation for 48 hours. Whole cells extracts, total RNA and chromatin were 
gained from control (C siRNA) and knockdown cells (MSK1 siRNA) that were left untreated or were 
stimulated with 188.5nM anisomycin and 165.5nM TSA (+ or A/T) for 1 hour. (A) Knockdown 
efficiency was analyzed by Western blot using an antibody against MSK1. Antibody against beta-
tubulin (tubulin) ensured equal loading. (B) p21 expression levels in control and MSK1 knockdown 
cells were monitored by qRT PCR, using GAPDH for normalization. (C) qRT-ChIP analysis was 
performed with antibodies specific for MSK1, H3S10phK14ac or an unspecific control antibody (IgG) 
and primers specific for the proximal p21 promoter. ChIP results are shown as percentage of input; for 
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Figure 4. PP2A acts as negative regulator of p21 expression. (A) Resting Swiss 3T3 cells obtained 
by serum deprivation for 72 hours were left untreated or treated for 5 hours as indicated with following 
concentrations 165.5 nM TSA (T), 188.5 nM anisomycin (A) or 50 nM okadaic acid (OA) alone or in 
combination. Expression of p21 mRNA was examined by qRT PCR, normalized to HPRT and is 
shown relative to untreated cells.  The difference in p21 expression between untreated and TSA treated 
cells is not significant (p-value: 0.051). (B) Proliferating Swiss 3T3 cells were induced with the same 
stimuli and for the same time period as described in panel (A). Total RNA was extracted and reverse 
transcribed cDNA was used for p21 expression analysis by qRT PCR as described for panel A. (C) 
qRT-ChIP analysis of proliferating Swiss 3T3 fibroblasts either left untreated or stimulated with 50 nM 
okadaic acid (OA) and 165.5 nM TSA (TSA) alone or simultaneously (OA/T) using a phosphoacetyl-
histone H3 antibody (H3S10phK14ac) or an unspecific antibody (IgG). (D) ChIP assay of a time 
course, in which resting cells were stimulated with 188.5nM anisomycin and 165.5nM TSA for short 
time periods (indicated in minutes), using an unspecific antibody (IgG) or antibodies specific for 
H3S10phK14ac, the catalytic subunit of PP2A and MSK1. ChIP results are shown as percentage of 
input; for histone modifications the values were corrected for changes in nucleosomal density. (E and 
F) Proliferating T98G cells were transfected with control siRNA oligonucleotides and siRNA 
oligonucleotides specifically targeting the two isoforms of the catalytic subunit of PP2A. Protein 
extracts and total RNA were gained from control (C siRNA) and knockdown cells (PP2A siRNA) that 
were left untreated or were stimulated with 188.5nM anisomycin and 165.5nM TSA (A/T) for 1 hour. 
(E) Knockdown efficiency was analyzed by Western blot using an antibody against the catalytic 
subunit of PP2A. An antibody specific for beta-tubulin was used to ensure equal loading. (F) p21 
mRNA expression levels in control and PP2A knockdown cells were monitored by qRT PCR, using 
GAPDH for normalization. 
 
Figure 5. 14-3-3 ζ is important for p21 activation. (A-C) Proliferating T98G cells were transfected 
with control siRNA oligonucleotides and siRNA oligonucleotides specifically targeting 14-3-3 ζ 
mRNA. Transfected T98G cells were arrested by serum deprivation. Whole cells extracts, total RNA 
and chromatin were gained from control (C siRNA) and knockdown cells (14-3-3 ζ siRNA) that were 
left untreated (rest) or were stimulated with 188.5nM anisomycin and 165.5nM TSA (A/T) for 1 hour. 
(A) Knockdown efficiency was analyzed by Western blot using an antibody against 14-3-3 ζ (14-3-3 
ζ). Equal loading was controlled with an antibody specific for beta-tubulin. (B) p21 expression levels in 
control and 14-3-3 ζ knockdown cells were monitored by Real Time PCR, using GAPDH for 
normalization. (C) qRT-ChIP assays using antibodies specific for 14-3-3 ζ, H3K14ac, H3S10phK14ac, 
the catalytic subunit of PP2A and an unspecific antibody (IgG) as control. ChIP results are shown as 
percentage of input; for histone modifications the values were corrected for changes in nucleosomal 
density. (D) In vitro phosphorylation assay and 14-3-3 protection. Phosphoacetylated histone H3 was 
incubated without (-) or with recombinant PP2A in the absence (PP2A) or presence of increasing 
amounts of recombinant 14-3-3 ζ. Phosphoacetylated histone H3 was detected with an H3S10phK14ac 
antibody and equal loading was confirmed with an antibody specific for the C-terminus of histone H3 
(cH3). Intensities of histone H3S10phK14ac signals were quantified by densitometric scanning and 
normalized to the loading control (cH3). 
 
Figure 6. Model for the regulation of the p21 gene by reversible phosphorylation and acetylation.  
In the absence of growth factor or stress signals HDACs and PP2A are present at the p21 promoter and 
the gene is silent. TSA-induced hyperacetylation is not sufficient for p21 activation. MAP kinase 
signaling leads to MSK1-mediated H3S10 phosphorylation and subsequent acetylation of H3K14. 
Inhibition of HDACs by TSA stabilizes the phosphoacetylation mark. The H3S10phK14ac mark is 
recognized and bound by 14-3-3 and thereby protected against PP2A activity. Presence of the 
H3S10phK14ac mark and 14-3-3 is required for RNA Pol II recruitment and p21 expression. 
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